MP07-08 EFFECT OF LUMASIRAN ON KIDNEY STONES AND NEPHROCALCINOSIS IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1
John C. Lieske(Mayo Clinic), Yaacov Frishberg(Shaare Zedek Medical Center), Jeffrey M. Saland(Université Claude Bernard Lyon 1), Mini Michael(Baylor College of Medicine), Sander F. Garrelfs(Emma Kinderziekenhuis), Taylor Ngo(Boehringer Ingelheim (Germany)), David J. Sas(Mayo Clinic), Tracy L. McGregor(Université Claude Bernard Lyon 1), John M. Gansner(Brigham and Women's Hospital)
Cited by 0
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach
|Kidney International|2013|350
ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling
|Journal of Clinical Investigation|2013|237
Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains
|Kidney International|2020|194
An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome
|The American Journal of Human Genetics|2018|184